Guardant Health (GH) director acquires 154 shares; holds 18,436
Guardant Health (GH) director Steve Krognes reported a Form 4 for an RSU conversion on 10/31/2025.
Rhea-AI Filing Summary
Guardant Health (GH) director Steve Krognes reported a Form 4 for an RSU conversion on 10/31/2025. A restricted stock unit vested and settled into 154 shares of common stock at a stated price of $0 (transaction code M). Following the transaction, he directly beneficially owned 18,436 shares of common stock and held 1,235 RSUs as derivative securities.
The RSU grant was made on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting in substantially equal monthly installments over the next three years. The filing was made by one reporting person in his capacity as a Director.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 154 | $0.00 | $0.00 |
| Exercise | Common Stock | 154 | $0.00 | $0.00 |
Footnotes (2)
- F1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.
- F2. Not applicable for Restricted Stock Units.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Guardant Health (GH) report in this Form 4?
How many RSUs remain outstanding for the reporting person?
What is the vesting schedule of the RSU grant?
What is the reporting person’s relationship to Guardant Health (GH)?
Was the Form 4 filed by one or multiple reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.